Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 260,000 Shares

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 260,000 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $18.23, for a total value of $4,739,800.00. Following the sale, the director directly owned 5,144,998 shares in the company, valued at $93,793,313.54. This trade represents a 4.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63.

Vor Biopharma Stock Performance

Shares of NASDAQ VOR opened at $16.27 on Tuesday. Vor Biopharma Inc. has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The firm has a market capitalization of $794.79 million, a PE ratio of -0.04 and a beta of 1.92. The stock’s 50-day simple moving average is $14.25 and its 200-day simple moving average is $17.35.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on VOR shares. Jefferies Financial Group started coverage on Vor Biopharma in a research report on Monday, March 30th. They set a “buy” rating and a $50.00 target price on the stock. TD Cowen started coverage on Vor Biopharma in a research report on Wednesday, December 17th. They set a “buy” rating on the stock. JPMorgan Chase & Co. cut their target price on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Wells Fargo & Company began coverage on Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, Wall Street Zen upgraded Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.67.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VOR. China Universal Asset Management Co. Ltd. purchased a new position in Vor Biopharma during the 4th quarter worth approximately $36,000. Goldman Sachs Group Inc. grew its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after buying an additional 58,247 shares during the last quarter. XTX Topco Ltd purchased a new position in Vor Biopharma during the 2nd quarter worth approximately $66,000. Chung Wu Investment Group LLC purchased a new position in Vor Biopharma during the 4th quarter worth approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new position in Vor Biopharma during the 4th quarter worth approximately $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).